Corneal Endothelial Dystrophy Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies – Aerie Pharma, Price Vision Group, Kowa Company, Trefoil Therapeutics and Others

August 17 18:14 2022
Corneal Endothelial Dystrophy Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - Aerie Pharma, Price Vision Group, Kowa Company, Trefoil Therapeutics and Others
Delveinsight Business Research LLP
As per DelveInsight, the Corneal Endothelial Dystrophy Therapeutics Market dynamics are expected to transform in the coming years owing to the launch of emerging therapies, the rise in the number of prevalent cases in the 7MM, ongoing Research and Development (R&D) activities, and the active participation of the global pharma and biotech giants in the therapeutic segment.

DelveInsight’s “Corneal Endothelial Dystrophy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Corneal Endothelial Dystrophy Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Corneal Endothelial Dystrophy market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Corneal Endothelial Dystrophy: An Overview

Corneal dystrophies are a group of rare genetic, often progressive, eye disorders in which abnormal material often accumulates in the clear (transparent) outer layer of the eye (cornea). There are more than 20 different types of corneal dystrophies, which are grouped into three categories.

The presence of corneal endothelial dystrophy may be found incidentally during a routine eye examination. A diagnosis may be confirmed by a thorough clinical evaluation, a detailed patient history, and a variety of tests, such as a slit lamp examination, in which a special microscope (slit lamp) allows a physician to view the eye through high magnification. Some specific corneal dystrophies can be diagnosed with molecular genetic tests even before symptoms develop.

Corneal Endothelial Dystrophy Market Key Facts

  • Corneal dystrophies can affect individuals of any age. Because some individuals do not have symptoms (asymptomatic), determining the true frequency of these disorders in the general population is difficult.

  • Through various secondary studies, it can be concluded Corneal dystrophies affect women and men in equal numbers, except for Fuchs corneal dystrophy, which affects women about four times as often as men.

  • According to the study titled “Corneal Dystrophy” by Moshirfar et al. (2020), in the United States, less than 0.01% of Americans are affected by corneal dystrophy (CD). It also stated the findings of another study which showed that around 530 persons out of a million in the United States have an endothelial-type CD.

Corneal Endothelial Dystrophy Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Corneal Endothelial Dystrophy market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report details the Corneal Endothelial Dystrophy market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

Corneal Endothelial Dystrophy Epidemiology

As per Delveinsight, the diagnosed prevalent cases of Corneal Endothelial Dystrophy are expected to increase in the 7MM during the forecast year, with an improvement in treatment pattern as well.

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Corneal Endothelial Dystrophy Epidemiology Segmentation

  • Prevalent Population of Corneal Dystrophy

  • Prevalent Population of Corneal Endothelial Dystrophy

  • Diagnosed and Treatable Cases of Corneal Endothelial Dystrophy

  • Type-specific Prevalent Population of Corneal Endothelial Dystrophy

Corneal Endothelial Dystrophy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Corneal Endothelial Dystrophy market or expected to get launched during the study period. The analysis covers Corneal Endothelial Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Corneal Endothelial Dystrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/corneal-endothelial-dystrophy-market

Corneal Endothelial Dystrophy Therapeutics Analysis

The dynamics of the Corneal Endothelial Dystrophy market are anticipated to change in the coming years owing to the improvement in the research and development undertaking. A few key players are involved in developing the therapies for Corneal Endothelial Dystrophy, which are expected to launch in the coming years.

Some of the key companies in the Corneal Endothelial Dystrophy market include:

  • Aerie Pharmaceuticals

  • Price Vision Group

  • Kowa Company

  • Trefoil Therapeutics

And others.

Corneal Endothelial Dystrophy Therapies covered in the report include 

  • Rhopressa

  • Glanatec

  • TTHX1114

And many others.

Get More Detailed Insights Into the Emerging Therapies & Key Companies –  https://www.delveinsight.com/sample-request/corneal-endothelial-dystrophy-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Corneal Endothelial Dystrophy Competitive Intelligence Analysis

4. Corneal Endothelial Dystrophy Market Overview at a Glance

5. Corneal Endothelial Dystrophy Disease Background and Overview

6. Corneal Endothelial Dystrophy Patient Journey

7. Corneal Endothelial Dystrophy Epidemiology and Patient Population

8. Corneal Endothelial Dystrophy Treatment Algorithm, Current Treatment, and Medical Practices

9. Corneal Endothelial Dystrophy Unmet Needs

10. Key Endpoints of Corneal Endothelial Dystrophy Treatment

11. Corneal Endothelial Dystrophy Marketed Products

12. Corneal Endothelial Dystrophy Emerging Therapies

13. Corneal Endothelial Dystrophy Seven Major Market Analysis

14. Attribute Analysis

15. Corneal Endothelial Dystrophy Market Outlook (7 major markets)

16. Corneal Endothelial Dystrophy Access and Reimbursement Overview

17. KOL Views on the Corneal Endothelial Dystrophy Market.

18. Corneal Endothelial Dystrophy Market Drivers

19. Corneal Endothelial Dystrophy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/corneal-endothelial-dystrophy-market

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

 

Other Trending Healthcare Report by DelveInsight

Mild Cognitive Impairment Market
“Mild Cognitive Impairment Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Mild Cognitive Impairment Market size, share, and trends in the 7MM. Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the Mild Cognitive Impairment therapeutics Market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

  Categories: